Xinwen Wang, Fupeng Zhang, Xi Yang, Meiping Xue, Xiaoli Li, Yu Gao, Likun Liu
Oncology Research, Vol.27, No.8, pp. 871-877, 2019, DOI:10.3727/096504018X15426271404407
Abstract Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI),
afatinib, has been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired
resistance to afatinib has not been well studied. In this study, we established afatinib acquired resistant cell
lines. Gene array technology was used to screen changes in gene expression between afatinib-resistant lung
cancer cells and parental cells. Our results showed that secreted phosphoprotein 1 (SPP1) was significantly
increased in afatinib-resistant lung cancer cells. To study the effect of SPP1 on afatinib resistance, siSPP1 was
used to knock down SSP1 More >
Login
Register
